Cancer nanomedicines: oversold or underappreciated?

Roy van der Meel*, Twan Lammers, Wim E. Hennink

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review


Since the approval of liposomal doxorubicin (Doxil) and daunorubicin (DaunoXome) 20 years ago for the treatment of (HIV-related) Kaposi’s sarcoma, significant investment and research efforts have been geared toward the development of nanomedicines for cancer treatment. The benefits of formulating cancer drugs in lipid- and polymer-based nanocarrier systems regarding drug solubility, circulation time, biodistribution, and toxicity while maintaining (or even enhancing) therapeutic efficacy, have led to the approval of about a dozen cancer nanomedicines, including antibody-drug conjugates (ADCs)
Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalExpert Opinion on Drug Delivery
Issue number1
Publication statusPublished - 2017


  • Cancer nanomedicines
  • Clinical translation
  • Clinical trials
  • Combination treatment
  • Drug delivery
  • Drug targeting
  • EPR effect
  • Triggered release


Dive into the research topics of 'Cancer nanomedicines: oversold or underappreciated?'. Together they form a unique fingerprint.

Cite this